Nausea affects 44% of GLP-1 users in clinical trials, doctors said, with vomiting, constipation, loose stools, reflux and burping among the most common side effects of drugs such as Ozempic, Wegovy and Zepbound.
Those problems stem from the medicines slowing stomach emptying and suppressing hunger and thirst, which can leave patients dehydrated and short on electrolytes, protein and fiber.
More serious complications can follow, including pancreatitis, gallstones, gallbladder inflammation, intestinal obstruction and kidney failure from severe vomiting; doctors said overlapping symptoms mean persistent nausea or vomiting should be reported quickly.
Doctors also flagged a small but serious risk of permanent gastroparesis and said reduced saliva can raise cavities and gum disease.
With long-term data still limited, physicians urged patients to use GLP-1s only within prescribing guidelines, stay hydrated, prioritize protein and contact their doctor if symptoms worsen.
Stopping GLP-1 drugs can raise heart attack risk. Is lifelong dependency the only safe option for the millions of users?
Lawsuits allege stomach paralysis and vision loss. Are the benefits of GLP-1 drugs worth these newly revealed permanent risks?
Navigating GLP-1 Agonists: Legal Challenges, Gastroparesis Risk, and Precision Medicine in 2026
Overview
As of May 2026, the landscape for GLP-1 receptor agonists is rapidly changing due to increased legal scrutiny and new regulatory responses. This shift is driven by a growing awareness of potential adverse effects, such as those highlighted by a July 2024 study linking Ozempic to a higher risk of sudden, sometimes permanent, vision loss. Following this study, there has been a surge in lawsuits and legal investigations into severe side effects. These developments are reshaping clinical practice, patient counseling, and liability considerations for healthcare providers, making the environment more complex and focused on patient safety.